<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
    <channel>
        <title>Vox Sanguinis via MedWorm.com</title>
        <description>MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Vox Sanguinis' source.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=Vox+Sanguinis&t=Vox+Sanguinis&s=Search&f=source]]></link>
        <lastBuildDate>Wed, 08 Feb 2012 17:42:14 +0100</lastBuildDate>
        <item>
            <title>Current incidence and residual risk of HIV, HBV and HCV at Canadian Blood Services</title>
            <link>http://www.medworm.com/index.php?rid=5649241&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2012.01584.x</link>
            <description>Estimates of the viral residual risk should be updated to reflect current incidence of infection in blood donors. Incidence rates were estimated for allogeneic whole‐blood donations made to Canadian Blood Services from 2006 to 2009 based on transmissible disease conversions of repeat donations within a 3‐year period. Residual risk was estimated as the incidence multiplied by the window period. The residual risk of HIV was 1 per 8 million donations, HCV 1 per 6·7 million donations and HBV 1 per 1·7 million donations. The residual risk remains low and has decreased for HCV since our previous estimates due to reduced incidence. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5649241</comments>
            <pubDate>Wed, 01 Feb 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5649241</guid>        </item>
        <item>
            <title>On the trail of anti‐CDE to unexpected highlights of the RHD*weak 4.3 allele in the Upper Austrian population</title>
            <link>http://www.medworm.com/index.php?rid=5649242&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2012.01586.x</link>
            <description>Conclusion  The RHD*weak 4.3 allele with markedly reduced antigen D expression was shown to be associated with an altered RHCE gene formation leading to the expression of CX and VS. Its frequency was estimated 1 in 854 among apparently D‐ Upper Austrian blood donors. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5649242</comments>
            <pubDate>Mon, 30 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5649242</guid>        </item>
        <item>
            <title>Diary of Events</title>
            <link>http://www.medworm.com/index.php?rid=5610034&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01574.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5610034</comments>
            <pubDate>Fri, 20 Jan 2012 22:05:55 +0100</pubDate>
            <guid isPermaLink="false">5610034</guid>        </item>
        <item>
            <title>Red cell microparticle enumeration: validation of a flow cytometric approach</title>
            <link>http://www.medworm.com/index.php?rid=5583363&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01577.x</link>
            <description>Conclusion  This method is a useful strategy to detect RBC MP counts across bio‐samples provided that the flow cytometer can reliably discriminate the size of the calibration beads. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5583363</comments>
            <pubDate>Wed, 11 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5583363</guid>        </item>
        <item>
            <title>Occurrence of hepatitis E virus RNA in plasma donations from Sweden, Germany and the United States</title>
            <link>http://www.medworm.com/index.php?rid=5572801&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01583.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5572801</comments>
            <pubDate>Fri, 06 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5572801</guid>        </item>
        <item>
            <title>Precise pH measuring of platelet concentrates containing additive solution – the impact of the temperature</title>
            <link>http://www.medworm.com/index.php?rid=5561265&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01578.x</link>
            <description>Conclusion  The dpH is dependent on different PAS‐IIIM/plasma ratios and pH range. For precise reporting of pH22, the respective dpH must be used if converting is necessary. Preferably, the pH should be reported at 37°C or measured directly at 22°C. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5561265</comments>
            <pubDate>Thu, 05 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5561265</guid>        </item>
        <item>
            <title>How new is new: the late sampling strategy with rapid bacterial screening of platelet concentrates?</title>
            <link>http://www.medworm.com/index.php?rid=5561264&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01579.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5561264</comments>
            <pubDate>Thu, 05 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5561264</guid>        </item>
        <item>
            <title>Platelet concentrate transport in pneumatic tube systems – does it work?</title>
            <link>http://www.medworm.com/index.php?rid=5561263&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01580.x</link>
            <description>Blood sample transport via pneumatic tube systems (PTS) reduces the turnaround time of laboratories, but it might influence analysis results. Its effect on platelet concentrates (PCs) is not known. Platelet function was investigated after single and multiple PTS transport in comparison with storage and irradiation. Optical and impedance aggregation, CD‐62, and microparticles changed as a result of storage, but not due to transport. Irradiation lowered platelet function independently. Multiple transport impaired thrombin receptor‐activating peptide‐induced aggregation. This investigation demonstrates the feasibility of PTS transport. As platelet function depends on storage, it may be more important to transfuse fresh PCs. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5561263</comments>
            <pubDate>Thu, 05 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5561263</guid>        </item>
        <item>
            <title>A qualitative and quantitative analysis of von Willebrand factor contained in a very high‐purity plasma‐derived FVIII concentrate</title>
            <link>http://www.medworm.com/index.php?rid=5583362&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01576.x</link>
            <description>Conclusions  In all the VHP pdFVIII (Factane®) batches studied, regardless of the level of VWF, the structure and capacity of VWF binding to FVIII and to platelet GPIb were fully preserved. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5583362</comments>
            <pubDate>Sun, 01 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5583362</guid>        </item>
        <item>
            <title>High‐yield Platelet units revealed immediate pH decline and delayed mitochondrial dysfunction during storage in 100% plasma as compared with storage in SSP+</title>
            <link>http://www.medworm.com/index.php?rid=5572800&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01581.x</link>
            <description>Conclusions  The use of SSP+ instead of plasma may reduce the risk of triggering pro‐apoptotic events in high‐yield PLT units. A rapid decline in pH in PLT units cannot be explained with initial elevated and prolonged high carbon dioxide levels and mitochondrial dysfunction. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5572800</comments>
            <pubDate>Sun, 01 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5572800</guid>        </item>
        <item>
            <title>How to improve blood safety with respect to bacterial contaminations?</title>
            <link>http://www.medworm.com/index.php?rid=5561262&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01582.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5561262</comments>
            <pubDate>Sun, 01 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5561262</guid>        </item>
        <item>
            <title>Diary of Events</title>
            <link>http://www.medworm.com/index.php?rid=5545194&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01565.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5545194</comments>
            <pubDate>Wed, 28 Dec 2011 14:01:05 +0100</pubDate>
            <guid isPermaLink="false">5545194</guid>        </item>
        <item>
            <title>Establishment of the first International Repository for Transfusion‐Relevant Bacteria Reference Strains: ISBT Working Party Transfusion‐Transmitted Infectious Diseases (WP‐TTID), Subgroup on Bacteria</title>
            <link>http://www.medworm.com/index.php?rid=5545193&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01510.x</link>
            <description>Conclusion  The study was undertaken as a proof of principle with the aim to demonstrate (i) the quality, stability and suitability of the bacterial strains for low‐titre spiking of blood components, (ii) the property of donor‐independent proliferation in PCs, and (iii) their suitability for worldwide shipping of deep frozen, blinded pathogenic bacteria. These aims were successfully fulfilled. The WHO Expert Committee Biological Standardisation has approved the adoption of these four bacteria strains as the first Repository for Transfusion‐Relevant Bacteria Reference Strains and, additionally, endorsed as a project the addition of six further bacteria strain preparations suitable for control of platelet contamination as the next step of enlargement of the repository. (Source: Vox S...</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5545193</comments>
            <pubDate>Wed, 28 Dec 2011 14:00:48 +0100</pubDate>
            <guid isPermaLink="false">5545193</guid>        </item>
        <item>
            <title>Passing the Baton</title>
            <link>http://www.medworm.com/index.php?rid=5545192&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01571.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5545192</comments>
            <pubDate>Wed, 28 Dec 2011 14:00:43 +0100</pubDate>
            <guid isPermaLink="false">5545192</guid>        </item>
        <item>
            <title>Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial</title>
            <link>http://www.medworm.com/index.php?rid=5545190&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01575.x</link>
            <description>Conclusions  Partial replacement of transfused FFP by fibrinogen increases fibrin clot formation at the expense of less improved thrombin generation. Coagulation factors other than fibrinogen alone are required for full restoration of haemostasis. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5545190</comments>
            <pubDate>Wed, 28 Dec 2011 13:59:08 +0100</pubDate>
            <guid isPermaLink="false">5545190</guid>        </item>
        <item>
            <title>Blood donors on teratogenic drugs and donor deferral periods in a clinical situation</title>
            <link>http://www.medworm.com/index.php?rid=5545191&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01566.x</link>
            <description>Deferral of blood donors taking teratogenic drugs is critical. From March 2008 to January 2009, we analysed stored blood specimens from donors who had taken teratogenic drugs and whose blood was transfused to women of childbearing age to determine the plasma concentration at the time of donation using high‐performance liquid chromatography. In total, 167 specimens were examined. The numbers of specimens exceeding the quantification limit were 7, 39, 4, 2 and 1 for finasteride, isotretinoin, acitretin, etretinate and dutasteride, respectively. Finasteride was beyond the recommended drug deferral period in one specimen. These results may help create practical deferral policies. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5545191</comments>
            <pubDate>Wed, 28 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5545191</guid>        </item>
        <item>
            <title>Reducing the incidence of TRALI in the UK: the results of screening for donor leucocyte antibodies and the development of national guidelines</title>
            <link>http://www.medworm.com/index.php?rid=5487868&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01570.x</link>
            <description>Conclusions  Female donors with leucocyte antibodies were identified in a stratified screening programme. Donors with antibodies were either directed to red cell donation or deferred. This process, combined with other measures that have already been introduced, is anticipated to further reduce the incidence of TRALI. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5487868</comments>
            <pubDate>Thu, 08 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5487868</guid>        </item>
        <item>
            <title>Clinical benefits and cost‐effectiveness of allogeneic red‐blood‐cell transfusion in severe symptomatic anaemia</title>
            <link>http://www.medworm.com/index.php?rid=5495478&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01573.x</link>
            <description>Conclusion  ARBC transfusion in anaemic patients is clinically beneficial and cost‐effective. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5495478</comments>
            <pubDate>Thu, 01 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5495478</guid>        </item>
        <item>
            <title>Inter‐laboratory comparison of different rapid methods for the detection of bacterial contamination in platelet concentrates</title>
            <link>http://www.medworm.com/index.php?rid=5487867&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01572.x</link>
            <description>Conclusions  Both BactiFlow and 23S rRNA RT‐PCR demonstrated a high sensitivity to detecting bacterial contamination in PCs. The Pan Genera Detection Assay had some shortcomings regarding sensitivity, especially for the detection of Gram‐negative strains. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5487867</comments>
            <pubDate>Thu, 01 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5487867</guid>        </item>
        <item>
            <title>Comparison of candidate vCJD in vitro diagnostic assays using identical sample sets</title>
            <link>http://www.medworm.com/index.php?rid=5458847&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01525.x</link>
            <description>Conclusion  The approach outlined has successfully compared in vitro diagnostics assays for their sensitivity and reproducibility and is a first step toward the evaluation of an assay suitable for blood donor screening/diagnosis of vCJD. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5458847</comments>
            <pubDate>Thu, 01 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5458847</guid>        </item>
        <item>
            <title>Patterns of blood product use among patients with myelodysplastic syndrome</title>
            <link>http://www.medworm.com/index.php?rid=5442142&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01568.x</link>
            <description>Conclusion  These data show a recent decline in blood product use for patients with MDS. Future studies are needed to further evaluate the reasons for this finding, specifically exploring the impact of newer medications on blood product use in patients with MDS. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5442142</comments>
            <pubDate>Fri, 25 Nov 2011 10:28:48 +0100</pubDate>
            <guid isPermaLink="false">5442142</guid>        </item>
        <item>
            <title>Freezing ‘stem cells’ in a bag and tube under various freezing conditions?</title>
            <link>http://www.medworm.com/index.php?rid=5432445&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01569.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5432445</comments>
            <pubDate>Tue, 22 Nov 2011 10:29:00 +0100</pubDate>
            <guid isPermaLink="false">5432445</guid>        </item>
        <item>
            <title>High‐throughput multiplex PCR genotyping for 35 red blood cell antigens in blood donors</title>
            <link>http://www.medworm.com/index.php?rid=5432447&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01542.x</link>
            <description>Conclusion  The study shows that in practice, this high‐throughput genotyping assay is feasible, fast and provides reliable results. Compared to serological testing, this molecular approach is also very cost‐efficient. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5432447</comments>
            <pubDate>Mon, 21 Nov 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5432447</guid>        </item>
        <item>
            <title>Administration of Prednisolone intravenously or Dexamethason orally in random donors reveals equal results in granulocyte collection: a single centre experience</title>
            <link>http://www.medworm.com/index.php?rid=5432446&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01567.x</link>
            <description>Since cytokine – mobilization for granulocyte collections in random donors – is not licensed in Austria, we investigated in a prospective analysis the effects of prednisolone or dexamethasone (DXM) in 153 donors (35 women/118 men) and in the collected products. Either prednisolone (50 mg) intravenously 4 h before granulocyte collection or DXM (8 mg) orally 12 h before collection was given. Collections were performed with the Cobe Spectra (CardianBCT, Lakewood). We recorded a significantly higher percentage of granulocytes in the peripheral blood of the DXM. However, the collected number of granulocytes was equal in both groups. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5432446</comments>
            <pubDate>Mon, 21 Nov 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5432446</guid>        </item>
        <item>
            <title>Evaluation of the hemostatic potential including thrombin generation of three different therapeutic pathogen‐reduced plasmas</title>
            <link>http://www.medworm.com/index.php?rid=5423133&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01562.x</link>
            <description>Conclusion  The hemostatic potential appears well preserved in all therapeutic plasmas tested but there are some differences between preparations, the clinical relevance of which remains to be elucidated. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5423133</comments>
            <pubDate>Sat, 19 Nov 2011 10:46:11 +0100</pubDate>
            <guid isPermaLink="false">5423133</guid>        </item>
        <item>
            <title>The pro‐inflammatory effects of platelet contamination in plasma and mitigation strategies for avoidance</title>
            <link>http://www.medworm.com/index.php?rid=5423134&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01559.x</link>
            <description>Conclusion  Platelet contamination causes sCD40L accumulation in stored plasma that may contribute to TRALI. Platelet reduction is potentially the first TRALI mitigation effort in plasma manufacturing. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5423134</comments>
            <pubDate>Fri, 18 Nov 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5423134</guid>        </item>
        <item>
            <title>Impact of solvent/detergent treatment of plasma on transfusion‐relevant bacteria</title>
            <link>http://www.medworm.com/index.php?rid=5423136&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01560.x</link>
            <description>Conclusion  The S/D treatment of plasma does not alter the bactericidal activity of complement, and inactivates some Gram‐positive bacteria. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5423136</comments>
            <pubDate>Thu, 17 Nov 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5423136</guid>        </item>
        <item>
            <title>Predicting massive blood transfusion using clinical scores post‐trauma</title>
            <link>http://www.medworm.com/index.php?rid=5423135&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01564.x</link>
            <description>Conclusions  The PWH score performs with similar accuracy when applied to an Australian population as in its derivation population. The relative simplicity of the PWH score makes it a viable tool for clinical use, although utility of such tools may be more suited for research in determining inclusion or exclusion criteria for comparative outcome studies. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5423135</comments>
            <pubDate>Thu, 17 Nov 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5423135</guid>        </item>
        <item>
            <title>Significant background rates of HBV and HCV infections in patients and risks of blood transfusion from donors with low anti‐HBc titres or high anti‐HBc titres with high anti‐HBs titres in Japan: a prospective, individual NAT study of transfusion‐transmitted HBV, HCV and HIV infections</title>
            <link>http://www.medworm.com/index.php?rid=5409595&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01561.x</link>
            <description>Conclusion  This study demonstrated that the current criteria employed by JRC have a low risk, but the background rates of HBV and HCV infections in Japanese patients are significant. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5409595</comments>
            <pubDate>Thu, 17 Nov 2011 01:28:55 +0100</pubDate>
            <guid isPermaLink="false">5409595</guid>        </item>
        <item>
            <title>Removal of prion infectivity by affinity ligand chromatography during OctaplasLG® manufacturing – results from animal bioassay studies</title>
            <link>http://www.medworm.com/index.php?rid=5388802&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01563.x</link>
            <description>Conclusion  Bioassay studies confirmed the capacity of the LG to bind brain‐derived MIC prion proteins spiked into plasma. Even through infectivity was still detected following passage over the LG, this can be attributed to the high loads used in the study design, and the binding capacity of the LG still ensures a significant safety margin – binding the prion agents at the levels of prion infectivity that might be present in plasma and beyond. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5388802</comments>
            <pubDate>Thu, 10 Nov 2011 11:36:15 +0100</pubDate>
            <guid isPermaLink="false">5388802</guid>        </item>
        <item>
            <title>Treatment of primary autoimmune thrombocytopenia (AITP) [1]</title>
            <link>http://www.medworm.com/index.php?rid=5388803&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.1552.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5388803</comments>
            <pubDate>Fri, 04 Nov 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5388803</guid>        </item>
        <item>
            <title>Author Index</title>
            <link>http://www.medworm.com/index.php?rid=5337205&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01547.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5337205</comments>
            <pubDate>Sat, 22 Oct 2011 23:21:16 +0100</pubDate>
            <guid isPermaLink="false">5337205</guid>        </item>
        <item>
            <title>Posters</title>
            <link>http://www.medworm.com/index.php?rid=5337204&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01546.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5337204</comments>
            <pubDate>Sat, 22 Oct 2011 23:21:14 +0100</pubDate>
            <guid isPermaLink="false">5337204</guid>        </item>
        <item>
            <title>Orals</title>
            <link>http://www.medworm.com/index.php?rid=5337203&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01545.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5337203</comments>
            <pubDate>Sat, 22 Oct 2011 23:21:12 +0100</pubDate>
            <guid isPermaLink="false">5337203</guid>        </item>
        <item>
            <title>Diary of Events</title>
            <link>http://www.medworm.com/index.php?rid=5316324&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01544.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5316324</comments>
            <pubDate>Sat, 15 Oct 2011 12:24:46 +0100</pubDate>
            <guid isPermaLink="false">5316324</guid>        </item>
        <item>
            <title>Deferral of males who had sex with other males</title>
            <link>http://www.medworm.com/index.php?rid=5316323&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01489.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5316323</comments>
            <pubDate>Sat, 15 Oct 2011 12:24:44 +0100</pubDate>
            <guid isPermaLink="false">5316323</guid>        </item>
        <item>
            <title>First‐time donors responding to a national disaster may be an untapped resource for the blood centre</title>
            <link>http://www.medworm.com/index.php?rid=5316322&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01557.x</link>
            <description>Conclusion  Post‐earthquake first‐time donors may be less likely to donate again without continuing motivation strategies. Further studies on PEFTD’s lack of motivation to return for donation are needed to design recruitment strategies to convert PEFTD to become repeat donors to continuously replenish the blood supply. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5316322</comments>
            <pubDate>Sat, 15 Oct 2011 12:23:21 +0100</pubDate>
            <guid isPermaLink="false">5316322</guid>        </item>
        <item>
            <title>Serratia marcescens strains implicated in adverse transfusion reactions form biofilms in platelet concentrates and demonstrate reduced detection by automated culture</title>
            <link>http://www.medworm.com/index.php?rid=5286663&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01550.x</link>
            <description>Conclusion S. marcescens strains associated with transfusion reactions form biofilms under platelet storage conditions, and initial biofilm formation correlates with missed detection of contaminated platelet concentrates by the BacT/ALERT system. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5286663</comments>
            <pubDate>Tue, 04 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5286663</guid>        </item>
        <item>
            <title>Letter to the Editor – Response to ‘How expanding voluntary non‐remunerated blood donations would benefit patients, donors and healthcare systems?’– F. Rossi, R. Perry, J. de Wit,T. Evers &amp; G. Folléa, Vox Sanguinis DOI: 10.1111/j.1423‐0410.2011.01495.x</title>
            <link>http://www.medworm.com/index.php?rid=5286662&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01551.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5286662</comments>
            <pubDate>Tue, 04 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5286662</guid>        </item>
        <item>
            <title>The Danish Blood Donor Study: a large, prospective cohort and biobank for medical research</title>
            <link>http://www.medworm.com/index.php?rid=5286661&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01553.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5286661</comments>
            <pubDate>Tue, 04 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5286661</guid>        </item>
        <item>
            <title>An international reference reagent for the detection of RHD and SRY DNA in plasma</title>
            <link>http://www.medworm.com/index.php?rid=5286660&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01543.x</link>
            <description>Conclusions  In October 2010, the WHO Expert Committee on Biological Standardization approved the material 07/222 as an International Reference Reagent for the detection of RHD and SRY DNA in plasma. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5286660</comments>
            <pubDate>Tue, 04 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5286660</guid>        </item>
        <item>
            <title>Benefit of transfusion‐related acute lung injury risk‐minimization measures – German haemovigilance data (2006–2010)</title>
            <link>http://www.medworm.com/index.php?rid=5286659&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01556.x</link>
            <description>Conclusion  The comparison of the pre‐ and the post‐implementation period demonstrated a significantly reduced risk of TRALI events comparing 2006/2007 with 2010 (P‐value: &amp;lt; 0·01). Furthermore, no case of TRALI‐induced fatality occurred after the implementation of risk‐minimization measures. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5286659</comments>
            <pubDate>Tue, 04 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5286659</guid>        </item>
        <item>
            <title>Collaborative study to establish a World Health Organization International genotype panel for parvovirus B19 DNA nucleic acid amplification technology (NAT)‐based assays</title>
            <link>http://www.medworm.com/index.php?rid=5305171&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01541.x</link>
            <description>Conclusions  The four‐member panel is intended for use in evaluating the ability of NAT assays to detect different B19V genotypes (M1–M3). Based on the results of the collaborative study, the panel was established as the 1st WHO International Reference Panel for parvovirus B19 genotypes. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5305171</comments>
            <pubDate>Sat, 01 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5305171</guid>        </item>
        <item>
            <title>Erratum</title>
            <link>http://www.medworm.com/index.php?rid=5286658&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01558.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5286658</comments>
            <pubDate>Sat, 01 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5286658</guid>        </item>
        <item>
            <title>Meta‐analysis of the studies of bleeding complications of platelets pathogen‐reduced with the Intercept system</title>
            <link>http://www.medworm.com/index.php?rid=5274789&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01555.x</link>
            <description>Conclusions  Treatment with Intercept may increase the risk of all and clinically significant (albeit not severe) bleeding complications in RCTs maintaining a platelet count of ≥10 × 109 or ≥20 × 109/l through increased platelet transfusions. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5274789</comments>
            <pubDate>Sat, 01 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5274789</guid>        </item>
        <item>
            <title>Deferral of males who had sex with other males</title>
            <link>http://www.medworm.com/index.php?rid=5261839&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.1489.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5261839</comments>
            <pubDate>Thu, 29 Sep 2011 10:20:51 +0100</pubDate>
            <guid isPermaLink="false">5261839</guid>        </item>
        <item>
            <title>Detection of hepatitis E virus RNA in plasma mini‐pools from blood donors in England</title>
            <link>http://www.medworm.com/index.php?rid=5274790&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01554.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5274790</comments>
            <pubDate>Thu, 29 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5274790</guid>        </item>
        <item>
            <title>Neutrophil antibody diagnostics and screening: review of the classical versus the emerging*</title>
            <link>http://www.medworm.com/index.php?rid=5239035&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01511.x</link>
            <description>Conclusions  To date, the number and specificity of test sera applied to each platform is small. This needs to be substantially increased and further rigorous serological evaluation is yet needed to compare the sensitivity and specificity limits of each new platform with classical methods. With a limited world supply of TRALI‐relevant test sera, a collaborative effort of laboratories with neutrophil and TRALI investigation expertise is required. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5239035</comments>
            <pubDate>Thu, 22 Sep 2011 11:19:51 +0100</pubDate>
            <guid isPermaLink="false">5239035</guid>        </item>
        <item>
            <title>International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009</title>
            <link>http://www.medworm.com/index.php?rid=5239036&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01506.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5239036</comments>
            <pubDate>Wed, 21 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5239036</guid>        </item>
        <item>
            <title>Paroxysmal nocturnal haemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test</title>
            <link>http://www.medworm.com/index.php?rid=5239037&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01530.x</link>
            <description>Conclusion  Eculizumab therapy for PNH should be added to the list of possible causes for a positive DAT. Intravascular haemolysis was inhibited by eculizumab, but signs of extravascular haemolysis should be monitored. Because renal iron loss was stopped, eculizumab‐treated pts can be prone to iron overload and therefore ferritin concentrations should be monitored closely. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5239037</comments>
            <pubDate>Mon, 19 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5239037</guid>        </item>
        <item>
            <title>Diary of Events</title>
            <link>http://www.medworm.com/index.php?rid=5227170&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01534.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5227170</comments>
            <pubDate>Mon, 19 Sep 2011 02:42:25 +0100</pubDate>
            <guid isPermaLink="false">5227170</guid>        </item>
        <item>
            <title>Quality controls of cryopreserved haematopoietic progenitor cells (peripheral blood, cord blood, bone marrow)</title>
            <link>http://www.medworm.com/index.php?rid=5227169&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01471.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5227169</comments>
            <pubDate>Mon, 19 Sep 2011 02:42:23 +0100</pubDate>
            <guid isPermaLink="false">5227169</guid>        </item>
        <item>
            <title>Adhesive interaction between peripheral blood mononuclear cells and activated platelets in the presence of anti‐human leukocyte antigen Class I alloantibody causes production of IL‐1β and IL‐8</title>
            <link>http://www.medworm.com/index.php?rid=5227165&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01549.x</link>
            <description>Conclusions:  The activation of platelets with anti‐HLA Class I alloantibody caused the formation of platelet–monocyte aggregates, followed by the production of IL‐1β and IL‐8, in a cognate antigen–antibody manner. The adhesive interaction of P‐selectin and PSGL‐1 at least partially contributed to these phenomena. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5227165</comments>
            <pubDate>Mon, 19 Sep 2011 02:41:05 +0100</pubDate>
            <guid isPermaLink="false">5227165</guid>        </item>
        <item>
            <title>Duration of Ross River viraemia in a mouse model – implications for transfusion transmission</title>
            <link>http://www.medworm.com/index.php?rid=5227168&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01536.x</link>
            <description>Conclusion  This study provides updated epidemiological data useful to underpin modelling to assess the potential risk of transfusion‐transmitted RRV. Using an established model for dengue, the risk estimate for RRV transmission is comparable in the same geographical region. Should transfusion be proven as a route of transmission, this supports consideration of appropriate mitigation strategies to safeguard blood recipients. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5227168</comments>
            <pubDate>Fri, 16 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5227168</guid>        </item>
        <item>
            <title>Thrombocytopenia at birth in neonates with red cell alloimmune haemolytic disease</title>
            <link>http://www.medworm.com/index.php?rid=5227167&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01539.x</link>
            <description>Conclusions  Thrombocytopenia at birth occurs in 26% of neonates with HDFN due to red cell alloimmunization and is independently associated with IUT treatment, SGA and lower gestational age at birth. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5227167</comments>
            <pubDate>Fri, 16 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5227167</guid>        </item>
        <item>
            <title>The effect of plasma removal from apheresis platelet concentrates on platelet function</title>
            <link>http://www.medworm.com/index.php?rid=5227166&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01548.x</link>
            <description>The effect of plasma removal on platelet function has scarcely been investigated. Plasma removal from apheresis platelet concentrates was achieved by centrifugation at 5000 g for 6 min or 2000 g for 10 min. After resting for 1 h, platelet concentrates were resuspended in 0·9% NaCl. Platelet function was tested before centrifugation and after resuspension by multiple electrode impedance aggregometry (MEA) and light transmission aggregometry (LTA). Plasma removal resulted in 10–14% lower response to TRAP‐6 by MEA using both washing procedures, whereas TRAP‐6‐inducible aggregation by LTA increased slightly (2–5%). Neither plasma removal method affected collagen‐induced aggregation. Thus, platelet function did not deteriorate significantly by either method. (Source: Vox ...</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5227166</comments>
            <pubDate>Fri, 16 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5227166</guid>        </item>
        <item>
            <title>The outcome of donor screening for Human T‐Cell Lymphotropic Virus infection in the Netherlands</title>
            <link>http://www.medworm.com/index.php?rid=5197021&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01538.x</link>
            <description>Conclusion  The lack of accurate estimators for infectivity and pathogenicity hampers the estimation of morbidity and mortality that HTLV‐infected transfusions would cause. Leucodepletion may be as effective as HTLV donor screening; its effect on HTLV transmission should be studied. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5197021</comments>
            <pubDate>Mon, 05 Sep 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5197021</guid>        </item>
        <item>
            <title>A standardized immunofluorescence test method with human neutrophil antigen‐expressing cell lines to enhance antibody detection</title>
            <link>http://www.medworm.com/index.php?rid=5184907&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01532.x</link>
            <description>There is an international need for a large‐scale human neutrophils antigen (HNA) antibody screening platform to minimize the risk of antibody‐mediated transfusion‐related acute lung injury. However, sourcing a substantial, reliable source of HNA, as well as the scarcity of well‐characterized HNA antisera for validating new screening platforms, remain as major obstacles. This short communication presents an improved protocol for the effective use of HNA‐expressing KY cells as a screening platform using eight well‐characterized HNA antisera of a single defined specificity. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5184907</comments>
            <pubDate>Tue, 30 Aug 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5184907</guid>        </item>
        <item>
            <title>Infectivity of pre‐seroconversion donations: an analysis of lookback exercises in the Netherlands, 2000–2006</title>
            <link>http://www.medworm.com/index.php?rid=5184906&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01537.x</link>
            <description>Conclusion  Among 39 recipients of pre‐seroconversion donations, 2 (5%) were found HBV infected by transfusion. The labour‐intensive lookback procedures did not reveal any conclusive transmissions additional to the infections detected by PCR testing of repository pre‐seroconversion samples. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5184906</comments>
            <pubDate>Tue, 30 Aug 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5184906</guid>        </item>
        <item>
            <title>Report of the Fourth International Workshop on molecular blood group genotyping</title>
            <link>http://www.medworm.com/index.php?rid=5197020&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01540.x</link>
            <description>The fourth International Society of Blood Transfusion (ISBT) workshop on molecular blood group genotyping was held in 2010, with a feedback meeting at the ISBT Congress in Berlin, Germany. Fifty laboratories participated, 17 more than in 2008. Six samples were distributed. Samples 1–3 were DNA samples for all red cell blood group tests available to the participants. Of the 46 laboratories that tested these samples, 37 obtained completely correct results, although the extent of testing varied considerably. Sample 4, also a DNA sample, was an Rh problem in which RHDΨ and RHCE*ceCF were present, but the participants were only informed that the donor’s red cells typed as positive with some monoclonal anti‐D. Of the 42 laboratories that participated in this exercise, seven performed the ...</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5197020</comments>
            <pubDate>Sun, 31 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5197020</guid>        </item>
        <item>
            <title>Placental immunology and maternal alloimmune responses</title>
            <link>http://www.medworm.com/index.php?rid=5184905&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01533.x</link>
            <description>During pregnancy, women are tolerant of their semi‐allogeneic fetus whilst not being immunosuppressed and indeed readily form alloantibodies. This ‘Immunological Paradox of Pregnancy’ may be explained by an understanding of placental anatomy and immunology. Trophoblast cells form the interface between the fetus and maternal tissues and blood and escape allorecognition because they lack classical human leucocyte antigen (HLA) class I and II molecules. Local immunoregulation, or tolerance, in the decidua is mediated partly by HLA‐G+ extravillous trophoblasts (EVT) that invade the tissue and prevent killing by maternal natural killer cells, cytotoxic T cells and macrophages. Placental hormones orchestrate the composition and regulatory function of maternal immune cells. In contrast, s...</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5184905</comments>
            <pubDate>Sun, 31 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5184905</guid>        </item>
        <item>
            <title>Expression of the Rh/RhAG complex is reduced in Mi.III erythrocytes</title>
            <link>http://www.medworm.com/index.php?rid=5163412&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01535.x</link>
            <description>Conclusion  Substitution of GPB with Gp.Mur significantly reduced the expression of Rh antigen and RhAG on the Mi.III+/+ erythrocyte membrane. The Mi.III phenotype is predicted to induce considerable structural variations within the band 3/Rh‐associated macrocomplexes. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5163412</comments>
            <pubDate>Sun, 31 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5163412</guid>        </item>
        <item>
            <title>Widespread distribution of hepatitis E virus in plasma fractionation pools</title>
            <link>http://www.medworm.com/index.php?rid=5089147&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01527.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5089147</comments>
            <pubDate>Sun, 31 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5089147</guid>        </item>
        <item>
            <title>The Dublin Consensus Statement 2011 on vital issues relating to the collection and provision of blood components and plasma‐derived medicinal products</title>
            <link>http://www.medworm.com/index.php?rid=5089146&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01528.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5089146</comments>
            <pubDate>Sun, 31 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5089146</guid>        </item>
        <item>
            <title>Safety and frequency of whole blood donations from elderly donors</title>
            <link>http://www.medworm.com/index.php?rid=5089145&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01531.x</link>
            <description>Conclusions  Elderly donors have very low adverse reaction frequencies and are highly committed to donate blood. Thus, we consider donations from repeat donors aged 69–70 safe and suggest it a powerful short‐ to midterm strategy to, at least partially, overcome the challenges of the demographic change. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5089145</comments>
            <pubDate>Sun, 31 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5089145</guid>        </item>
        <item>
            <title>ABO‐mismatched transfusions are not over‐represented in febrile non‐haemolytic transfusion reactions to platelets</title>
            <link>http://www.medworm.com/index.php?rid=5053657&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01529.x</link>
            <description>ABO‐mismatched plasma and platelet (PLT) transfusion have been associated with worse outcomes, including haemolysis and other reactions, compared to recipients of ABO‐identical products. The immune complexes that form in a mismatched transfusion have been demonstrated to stimulate pyrogenic cytokine release in vitro. Comparing ABO identical vs. ABO mismatched PLT transfusions, we found no significant difference in the ABO compatibilities between the PLT doses implicated in causing febrile non‐haemolytic transfusion reactions (FNHTR) in 162 recipients and both the baseline PLT donor/recipient ABO compatibility (P = 0·67) or the PLTs issued in the 30 days preceding the FNHTR (P = 0·92). ABO‐mismatched PLT transfusions do not appear to be aetiological agents of FNHTR in a ...</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5053657</comments>
            <pubDate>Sat, 23 Jul 2011 17:22:03 +0100</pubDate>
            <guid isPermaLink="false">5053657</guid>        </item>
        <item>
            <title>Variability of parvovirus B19 genotype 2 in plasma products with different compositions in the inactivation sensitivity by liquid‐heating</title>
            <link>http://www.medworm.com/index.php?rid=5053660&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01523.x</link>
            <description>Conclusion  Both genotypes 1 and 2 of B19 varied in sensitivity to liquid‐heating and low pH among different plasma preparations. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5053660</comments>
            <pubDate>Thu, 21 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5053660</guid>        </item>
        <item>
            <title>Iron studies and red cell transfusion in cardiothoracic and orthopaedic surgical patients: a retrospective audit at a tertiary hospital</title>
            <link>http://www.medworm.com/index.php?rid=5053659&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01524.x</link>
            <description>Conclusion  Iron studies were more commonly requested postoperatively despite many being anaemic at admission. A higher proportion of patients with postoperative iron studies had AI, and few had classical IDA or normal iron parameters, suggesting a transient inflammatory effect of surgery. This may mask underlying IDA or normal iron parameters and affect treatment. Preadmission assessment, including iron status, should be emphasized allowing diagnosis and correction of presurgical anaemia with treatment modalities other than red cell transfusion. In the postsurgical setting, consideration of a restrictive transfusion regimen sufficient to alleviate a patient’s clinical symptoms would ensure that this valuable resource is appropriately used. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5053659</comments>
            <pubDate>Thu, 21 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5053659</guid>        </item>
        <item>
            <title>Risk‐based decision‐making for blood safety: preliminary report of a consensus conference</title>
            <link>http://www.medworm.com/index.php?rid=5053658&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01526.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5053658</comments>
            <pubDate>Thu, 21 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5053658</guid>        </item>
        <item>
            <title>Complement activation products in liquid stored plasma and C3a kinetics after transfusion of autologous plasma</title>
            <link>http://www.medworm.com/index.php?rid=5040820&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01522.x</link>
            <description>Conclusion  Plasma components prepared by different methods and stored in the liquid phase differ significantly in the amount and timing of complement activation. C3a‐desArg present in plasma is rapidly eliminated after transfusion. Autologous plasma could be used to study complement kinetics in different clinical situations. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5040820</comments>
            <pubDate>Wed, 20 Jul 2011 18:34:53 +0100</pubDate>
            <guid isPermaLink="false">5040820</guid>        </item>
        <item>
            <title>Pathogen inactivation of plasma components</title>
            <link>http://www.medworm.com/index.php?rid=5040822&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01515.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5040822</comments>
            <pubDate>Mon, 18 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5040822</guid>        </item>
        <item>
            <title>Feasibility of a closed‐system cell processor (ACP215) for automated preparation of washed platelet concentrates</title>
            <link>http://www.medworm.com/index.php?rid=5040821&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01520.x</link>
            <description>Conclusion  The ACP215 system is a feasible alternative to manual, labour‐intensive, techniques for preparing washed platelet concentrates. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5040821</comments>
            <pubDate>Mon, 18 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5040821</guid>        </item>
        <item>
            <title>Fresh frozen plasma quality: relation to age and gender of blood donors</title>
            <link>http://www.medworm.com/index.php?rid=5031272&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01518.x</link>
            <description>Conclusion  International Normalized Ratio, aPTT, FVIII, FV, fibrinogen and protein S, as quality indicators for the efficacy of therapeutic plasma, revealed a moderate correlation with age and gender. Compared with the usual reference ranges, the differences were not significant enough to identify any relevant imbalance between procoagulating, anticoagulating and fibrinolytic factors that might influence product quality where the increasing age of the donors or the preference of male donor plasma was concerned. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5031272</comments>
            <pubDate>Sat, 16 Jul 2011 17:33:37 +0100</pubDate>
            <guid isPermaLink="false">5031272</guid>        </item>
        <item>
            <title>Diary of Events</title>
            <link>http://www.medworm.com/index.php?rid=5021746&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01513.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5021746</comments>
            <pubDate>Wed, 13 Jul 2011 17:44:07 +0100</pubDate>
            <guid isPermaLink="false">5021746</guid>        </item>
        <item>
            <title>Press Review</title>
            <link>http://www.medworm.com/index.php?rid=5021745&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01461.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5021745</comments>
            <pubDate>Wed, 13 Jul 2011 17:44:05 +0100</pubDate>
            <guid isPermaLink="false">5021745</guid>        </item>
        <item>
            <title>Prevention and treatment of coagulopathy in patients receiving massive transfusions</title>
            <link>http://www.medworm.com/index.php?rid=5021744&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01472.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5021744</comments>
            <pubDate>Wed, 13 Jul 2011 17:44:03 +0100</pubDate>
            <guid isPermaLink="false">5021744</guid>        </item>
        <item>
            <title>Response Letter</title>
            <link>http://www.medworm.com/index.php?rid=5021742&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01516.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5021742</comments>
            <pubDate>Wed, 13 Jul 2011 17:43:43 +0100</pubDate>
            <guid isPermaLink="false">5021742</guid>        </item>
        <item>
            <title>An improved Fc function assay utilizing CMV antigen‐coated red blood cells generated with synthetic function–spacer–lipid constructs</title>
            <link>http://www.medworm.com/index.php?rid=5021743&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01512.x</link>
            <description>Conclusion  The use of CMV kodecytes was shown to be a convenient means of generating red cells for the determination of Fc function of immunoglobulin products and offers the possibility of significantly reducing the time required to perform this assay. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5021743</comments>
            <pubDate>Mon, 11 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5021743</guid>        </item>
        <item>
            <title>Red‐blood‐cell alloimmunization and number of red‐blood‐cell transfusions</title>
            <link>http://www.medworm.com/index.php?rid=5000043&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01517.x</link>
            <description>Conclusion  The risk to develop a first red‐blood‐cells alloantibody increases up to the 40th transfusion and is similar for men and women. More data are needed to examine the risk after 40th transfusion. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5000043</comments>
            <pubDate>Tue, 05 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5000043</guid>        </item>
        <item>
            <title>Establishment of the first International Repository for Transfusion‐Relevant Bacteria Reference Strains</title>
            <link>http://www.medworm.com/index.php?rid=5010566&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01510.x</link>
            <description>Conclusion  The study was undertaken as a proof of principle with the aim to demonstrate (i) the quality, stability and suitability of the bacterial strains for low‐titre spiking of blood components, (ii) the property of donor‐independent proliferation in PCs, and (iii) their suitability for worldwide shipping of deep frozen, blinded pathogenic bacteria. These aims were successfully fulfilled. The WHO Expert Committee Biological Standardisation has approved the adoption of these four bacteria strains as the first Repository for Transfusion‐Relevant Bacteria Reference Strains and, additionally, endorsed as a project the addition of six further bacteria strain preparations suitable for control of platelet contamination as the next step of enlargement of the repository. (Source: Vox S...</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5010566</comments>
            <pubDate>Thu, 30 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5010566</guid>        </item>
        <item>
            <title>Molecular basis of the rare gene complex, DIVa(C)‐, which encodes four low‐prevalence antigens in the Rh blood group system</title>
            <link>http://www.medworm.com/index.php?rid=5000042&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01519.x</link>
            <description>Conclusions  The RHD*DIVa.2 encodes the Goa antigen, whereas the compound hybrid allele most likely encodes Rh33, Riv and FPTT. The weakly expressed C antigen on RBCs with the DIVa(C)‐ phenotype could be encoded by exons 2 and 3 from RHD*DIVa.2 in the compound hybrid. This is the first report of RHD*DIVa.2 being involved in a hybrid gene at the RHCE locus. As only one example of anti‐Riv has been described, our molecular analysis and findings provide a tool by which to predict Riv expression. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5000042</comments>
            <pubDate>Thu, 30 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5000042</guid>        </item>
        <item>
            <title>Deferral from donating blood of men who have sex with men: impact on the risk of HIV transmission by transfusion in France</title>
            <link>http://www.medworm.com/index.php?rid=4955179&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01509.x</link>
            <description>Conclusions  Changing the current MSM deferral policy may increase the risk of transfusion–transmission of HIV. However, this does not take into account a possible better compliance with MSM with a less stringent policy that would be perceived as more equitable. Conversely, relaxing the policy could encourage some MSM to seek an HIV test in blood centres. Thus, further qualitative study is needed to assess possible changes in compliance linked to a new policy. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4955179</comments>
            <pubDate>Wed, 22 Jun 2011 17:59:07 +0100</pubDate>
            <guid isPermaLink="false">4955179</guid>        </item>
        <item>
            <title>Diary of Events</title>
            <link>http://www.medworm.com/index.php?rid=4938774&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01508.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4938774</comments>
            <pubDate>Sat, 18 Jun 2011 17:45:04 +0100</pubDate>
            <guid isPermaLink="false">4938774</guid>        </item>
        <item>
            <title>Retraction: Boldt J, Mengistu A, Seyfert UT, Vogt A, Hellstern P: The impact of a medium molecular weight, low molar substitution hydroxyethyl starch dissolved in a physiologically balanced electrolyte solution on blood coagulation and platelet function in vitro. Vox Sang 2007; 93: 139–144</title>
            <link>http://www.medworm.com/index.php?rid=4938773&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01514.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4938773</comments>
            <pubDate>Sat, 18 Jun 2011 17:45:03 +0100</pubDate>
            <guid isPermaLink="false">4938773</guid>        </item>
        <item>
            <title>Transfusion Therapy: Clinical Principles and Practice</title>
            <link>http://www.medworm.com/index.php?rid=4854975&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01505.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4854975</comments>
            <pubDate>Tue, 24 May 2011 17:37:18 +0100</pubDate>
            <guid isPermaLink="false">4854975</guid>        </item>
        <item>
            <title>Prevalence and specificity of red‐blood‐cell antibodies in a multiethnic South and East Asian patient population and influence of using novel MUT+Mur+ kodecytes on its detection</title>
            <link>http://www.medworm.com/index.php?rid=4843450&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01507.x</link>
            <description>Conclusion  Antibodies to vMNS antigens are common in South and East Asian populations and are often missed when using standard screening cells. Use of specifically engineered screening cells to express red‐cell antigens artificially is beneficial in detecting the diverse alloantibodies present in our population. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4843450</comments>
            <pubDate>Fri, 20 May 2011 16:54:02 +0100</pubDate>
            <guid isPermaLink="false">4843450</guid>        </item>
        <item>
            <title>A novel Bweak hybrid allele lacks three enhancer repeats but generates normal ABO transcript levels</title>
            <link>http://www.medworm.com/index.php?rid=4843451&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01497.x</link>
            <description>Conclusion  We describe here the first hybrid between an O2 and a B allele and characterized the associated decrease in B antigen expression. Although it lacks three enhancer repeat units compared to common B alleles, the resulting transcript level was unaltered. This study challenges previous suggestions that the number of 43‐bp motifs in the ABO enhancer determines transcription rates in erythroid cells. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4843451</comments>
            <pubDate>Wed, 18 May 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4843451</guid>        </item>
        <item>
            <title>Corrigendum</title>
            <link>http://www.medworm.com/index.php?rid=4832692&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01496.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4832692</comments>
            <pubDate>Wed, 18 May 2011 18:46:04 +0100</pubDate>
            <guid isPermaLink="false">4832692</guid>        </item>
        <item>
            <title>Author Index</title>
            <link>http://www.medworm.com/index.php?rid=4832691&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01499.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4832691</comments>
            <pubDate>Wed, 18 May 2011 18:46:03 +0100</pubDate>
            <guid isPermaLink="false">4832691</guid>        </item>
        <item>
            <title>Poster Abstracts</title>
            <link>http://www.medworm.com/index.php?rid=4832690&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01498_2.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4832690</comments>
            <pubDate>Wed, 18 May 2011 18:46:02 +0100</pubDate>
            <guid isPermaLink="false">4832690</guid>        </item>
        <item>
            <title>Oral Abstracts</title>
            <link>http://www.medworm.com/index.php?rid=4832688&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01498_1.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4832688</comments>
            <pubDate>Wed, 18 May 2011 18:46:01 +0100</pubDate>
            <guid isPermaLink="false">4832688</guid>        </item>
        <item>
            <title>Clinical relevance of the HLA system in blood transfusion</title>
            <link>http://www.medworm.com/index.php?rid=4776550&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01474.x</link>
            <description>HLA alloimmunization induced by pregnancy, multiple transfusions or transplantation is responsible for some of the serious complications seen in patients receiving blood and blood products. These complications are primarily the result of antibody and antigen triggering an acute immunological reaction, which in some cases can be fatal e.g. TRALI. Some adverse reactions are triggered by HLA antibodies present in the patient whereas others are initiated by antibodies or HLA reactive cells present in the transfused product. The introduction of universal leucodepletion for the prevention of vCJD transmission has resulted in a significant reduction in these reactions by eliminating the main source of alloimmunization, but residual cellular components or platelets are still able to activate the i...</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4776550</comments>
            <pubDate>Mon, 02 May 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4776550</guid>        </item>
        <item>
            <title>Fibrinogen concentrates for bleeding trauma patients: what is the evidence?</title>
            <link>http://www.medworm.com/index.php?rid=4776549&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01478.x</link>
            <description>Conclusion  Evidence for the use of fibrinogen concentrate to trauma patients with massive bleeding is lacking. Well‐designed prospective, randomized, double‐blinded studies evaluating the effect of fibrinogen concentrate, as the only intervention, are urgently needed. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4776549</comments>
            <pubDate>Mon, 02 May 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4776549</guid>        </item>
        <item>
            <title>A re‐evaluation of the risk of transfusion‐transmitted HIV prevented by the exclusion of men who have sex with men from blood donation in England and Wales, 2005–2007</title>
            <link>http://www.medworm.com/index.php?rid=4776548&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01491.x</link>
            <description>Conclusion  If prevalence is the only factor affected by a reduced deferral, then the increased risk of HIV is probably negligible. However, the impact of a change depends on compliance; if this stays the same or worsens, the risk is expected to increase because of more incident infections in MSM who donate blood. The risk of transfusion‐transmitted HIV could probably be reduced further by improving compliance with any exclusion, particularly after recent risk behaviours. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4776548</comments>
            <pubDate>Mon, 02 May 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4776548</guid>        </item>
        <item>
            <title>The safety of blood donation by elderly blood donors</title>
            <link>http://www.medworm.com/index.php?rid=4776547&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01492.x</link>
            <description>Conclusions  Our data confirm that elderly regular blood donors may safely continue blood donation at least to the age of 71. Based on these data, we increased the upper age limit. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4776547</comments>
            <pubDate>Mon, 02 May 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4776547</guid>        </item>
        <item>
            <title>Quality control of leucocyte‐reduced blood components: overestimation of WBC content due to nucleated red blood cells</title>
            <link>http://www.medworm.com/index.php?rid=4814686&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01504.x</link>
            <description>Most methods for quality control of white blood cell (WBC) depletion in blood products are based on flow cytometric techniques. Nearly all commercial kits are based on propidium iodide staining of the DNA and subsequently counting those DNA based events as residual WBC. Here, we could show that a substantial proportion of those events are derived from nucleated red blood cells and therefore not specific for WBCs (e.g. in erythrocyte products 30%). We developed a flow cytometric method for residual WBC counting applying simultaneous DNA‐ and WBC‐specific surface staining to enable this. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4814686</comments>
            <pubDate>Sat, 30 Apr 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4814686</guid>        </item>
        <item>
            <title>Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products</title>
            <link>http://www.medworm.com/index.php?rid=4790763&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01502.x</link>
            <description>Conclusions  Kallikrein and FXIa are the major contaminants in IVIGs. FXIa was highly procoagulant, with highest level in TEE‐associated IVIGs. Since the NAPTT unambiguously identified FXIa procoagulant activity in IVIGs, its implementation as a release test would improve the safety of IVIGs. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4790763</comments>
            <pubDate>Sat, 30 Apr 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4790763</guid>        </item>
        <item>
            <title>Factors associated with fainting – before, during and after whole blood donation</title>
            <link>http://www.medworm.com/index.php?rid=4776546&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01494.x</link>
            <description>Conclusions  Variability in factors associated with fainting across defined periods of the donation process suggest differing underlying mechanisms and the possibility that interventions for the reactions most associated with injury during each time period can be designed. The highest rate of injury per donation occurred in ambulating donors. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4776546</comments>
            <pubDate>Sat, 30 Apr 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4776546</guid>        </item>
        <item>
            <title>In vitro quality of platelets during prolonged storage after washing with three platelet additive solutions</title>
            <link>http://www.medworm.com/index.php?rid=4764195&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01500.x</link>
            <description>Conclusion  PLTs washed with T‐Sol, Composol or SSP+ had good in vitro quality for two days after washing despite absence of glucose. PLTs in T‐Sol were more affected by the washing procedure and subsequent storage than Composol or SSP+ PLTs as judged by higher spontaneous activation. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4764195</comments>
            <pubDate>Fri, 29 Apr 2011 21:02:30 +0100</pubDate>
            <guid isPermaLink="false">4764195</guid>        </item>
        <item>
            <title>Net haemoglobin increase from reinfusion of refrigerated vs. frozen red blood cells after autologous blood transfusions</title>
            <link>http://www.medworm.com/index.php?rid=4764197&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01493.x</link>
            <description>Conclusion  The relatively larger recovery from anaemia in the frozen group during storage more than compensated for the larger loss of haemoglobin during freezing and resulted in a larger net gain in haemoglobin. Based on the average 23 g per week recovery of haemoglobin, extending refrigerated storage to 7–8 weeks may yield sufficient time for patients to fully replenish harvested haemoglobin from three bags of blood without reliance on frozen storage of RBC. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4764197</comments>
            <pubDate>Wed, 27 Apr 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4764197</guid>        </item>
        <item>
            <title>A spatial regression analysis of German community characteristics associated with voluntary non‐remunerated blood donor rates</title>
            <link>http://www.medworm.com/index.php?rid=4764196&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01501.x</link>
            <description>Conclusions  Blood donation appears to be a highly clustered regional phenomenon, suggesting the need for regionally targeted recruiting efforts and careful consideration of the value of mobile donation sites. Our model further suggests that municipalities with a decreasing percentage of 18‐ to 24‐year‐olds and an increasing percentage of older inhabitants may experience substantial declines in future blood donations. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4764196</comments>
            <pubDate>Wed, 27 Apr 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4764196</guid>        </item>
        <item>
            <title>A chromatographically purified human TGF‐β1 fraction from virally inactivated platelet lysates</title>
            <link>http://www.medworm.com/index.php?rid=4755350&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01486.x</link>
            <description>Conclusion  A fraction enriched in TGF‐β1 can be prepared from virally inactivated human platelet lysates using an easily scale process. Its interest in regenerative medicine and cell therapy will be evaluated in further studies. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4755350</comments>
            <pubDate>Wed, 27 Apr 2011 17:20:20 +0100</pubDate>
            <guid isPermaLink="false">4755350</guid>        </item>
        <item>
            <title>Motivations for donating blood and reasons why people lapse or never donate in Leeds, England: a 2001 questionnaire‐based survey</title>
            <link>http://www.medworm.com/index.php?rid=4749328&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01488.x</link>
            <description>Blood donors’ motivations and reasons for lapsing and never donating were determined from a questionnaire completed by 489 adults (89 regular donors, 105 lapsed donors, 295 never donors) in Leeds, UK. The free text responses were classified according to themes that arose. Altruistic motivations including reciprocation and kinship towards family, friends, and unknowns were most numerous. Other motivations related to the NHS or National Blood Service, obligation, occupation, self‐interest, convenience, peer‐influence, health benefits, a rare blood group, donations being useful, a TV programme, or ethnicity. Reasons for non‐donation were personal, medical, donation centre‐ or procedure‐related, exclusions, and age‐related. Suggestions are offered to increase the blood supply. (S...</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4749328</comments>
            <pubDate>Tue, 26 Apr 2011 15:07:19 +0100</pubDate>
            <guid isPermaLink="false">4749328</guid>        </item>
        <item>
            <title>Time‐based analysis of the apheresis platelet supply chain in England</title>
            <link>http://www.medworm.com/index.php?rid=4755351&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01483.x</link>
            <description>During 2009/2010 loss of platelets within NHS Blood and Transplant (NHSBT) due to time expiry was 9·3%. Hospitals remain reluctant to hold stocks of platelets due to the poor shelf life at issue. The purpose of this study was to identify areas for time compression in the apheresis platelet supply chain to extend the shelf life available for hospitals and reduce wastage in NHSBT. This was done within the context of NHSBT reconfiguring their supply chain and moving towards a consolidated and centralised approach. Time based process mapping was applied to identify value and non‐value adding time in two manufacturing models. A large amount of the non‐value adding time in the apheresis platelet supply chain is due to transportation and waiting for the next process in the manufacturing proc...</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4755351</comments>
            <pubDate>Mon, 25 Apr 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4755351</guid>        </item>
        <item>
            <title>Transfusion practices in massive haemorrhage in pre‐intensive and intensive care</title>
            <link>http://www.medworm.com/index.php?rid=4749331&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01482.x</link>
            <description>Conclusions  Patients who died early were coagulopathic before and on ICU admission and did not correct their coagulopathy. This study also shows that coagulopathy is associated with an increased risk of mortality. Early and aggressive correction of coagulopathy for patients presenting with coagulopathy may be effective in improving mortality. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4749331</comments>
            <pubDate>Sun, 24 Apr 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4749331</guid>        </item>
        <item>
            <title>Mobilized allogeneic peripheral stem/progenitor cell apheresis with Spectra Optia v.5·0, a novel, automatic interface‐controlled apheresis system: results from the first feasibility trial</title>
            <link>http://www.medworm.com/index.php?rid=4749330&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01484.x</link>
            <description>Conclusion  The automatic apheresis system Spectra Optia is functional and user‐friendly. Thus Spectra Optia aphereses are associated with similar, and equally variable, collection efficiencies as COBE Spectra MNC. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4749330</comments>
            <pubDate>Sun, 24 Apr 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4749330</guid>        </item>
        <item>
            <title>Extension of platelet shelf life from 4 to 5 days by implementation of a new screening strategy in Germany</title>
            <link>http://www.medworm.com/index.php?rid=4749329&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01485.x</link>
            <description>Conclusions  A late sample collection on day 3, day 4 or day 5 after blood donation in combination with a rapid bacterial detection method offers a new opportunity to improve blood safety and reduce errors due to sampling., BacT/ALERT, Bactiflow or 16s ID‐NAT are feasible for late bacterial screening in platelets may provide data which support the extension of platelet shelf life in Germany to 5 days. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4749329</comments>
            <pubDate>Sun, 24 Apr 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4749329</guid>        </item>
        <item>
            <title>Eurobloodpack: a common European design for blood bag systems with integral leucodepletion filters</title>
            <link>http://www.medworm.com/index.php?rid=4726546&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01480.x</link>
            <description>Three EBA specified blood bag configurations (‘Eurobloodpack’) are described which are capable of meeting &amp;gt;80% of its member’s requirements. These include a ‘top‐and‐top’ and two ‘bottom‐and‐top’ packs enabling aseptic, pre‐donation collection of up to 40 ml of samples, 427·5–522·5 ml of whole blood and the preparation of an extensive range of blood components. Features currently beyond the scope of ISO standardisation have been controlled including: anticoagulant and additive volumes; collection needle and sampling system; transfer tubing; cross‐match line; base label; leucodepletion filter performance; compatibility of access ports and transfusion sets. Eurobloodpack has significant advantages for blood services and blood bag manufacturers. (Source: V...</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4726546</comments>
            <pubDate>Tue, 19 Apr 2011 17:38:44 +0100</pubDate>
            <guid isPermaLink="false">4726546</guid>        </item>
        <item>
            <title>How expanding voluntary non‐remunerated blood donations would benefit patients, donors and healthcare systems?</title>
            <link>http://www.medworm.com/index.php?rid=4726547&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01495.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4726547</comments>
            <pubDate>Sat, 16 Apr 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4726547</guid>        </item>
        <item>
            <title>Donor safety comes first</title>
            <link>http://www.medworm.com/index.php?rid=4716048&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01490.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4716048</comments>
            <pubDate>Fri, 15 Apr 2011 18:42:08 +0100</pubDate>
            <guid isPermaLink="false">4716048</guid>        </item>
        <item>
            <title>Storage induced apoptosis of peripheral blood mononuclear cells obtained from leucoreduction system chambers</title>
            <link>http://www.medworm.com/index.php?rid=4716052&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01473.x</link>
            <description>Conclusion  PBMCs stored in autologous plasma in PVC‐bags at room temperature did not show an increase of 7‐AAD‐positive PBMCs during 24 h prior to cell processing but increased significantly thereafter. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4716052</comments>
            <pubDate>Thu, 14 Apr 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4716052</guid>        </item>
        <item>
            <title>Effect of X‐irradiation on the quality of red cell concentrates</title>
            <link>http://www.medworm.com/index.php?rid=4716051&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01479.x</link>
            <description>Conclusion  X‐irradiation of RCC in SAG‐M or IUT or RCC in plasma suitable for neonatal exchange transfusion resulted in acceptable levels of haemolysis and potassium leakage compared with the current process of gamma irradiation. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4716051</comments>
            <pubDate>Thu, 14 Apr 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4716051</guid>        </item>
        <item>
            <title>Comparison of platelet activation in platelet concentrates measured by flow cytometry or ADVIA 2120</title>
            <link>http://www.medworm.com/index.php?rid=4716050&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01469.x</link>
            <description>Conclusion  The usefulness of ADVIA platelet granularity measures to predict the degree of platelet activation depends upon the anticoagulant present in the platelet concentrate, and whether extra EDTA is added to the sample. Although ADVIA MPC and PCDW measurement could not replace CD62P or other gold standard methods of assessing platelet activation, these ADVIA 2120 parameters may provide a quick check of platelet concentrate quality. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4716050</comments>
            <pubDate>Thu, 14 Apr 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4716050</guid>        </item>
        <item>
            <title>The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover</title>
            <link>http://www.medworm.com/index.php?rid=4716049&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01477.x</link>
            <description>Conclusion  Despite the observed differences in platelet metabolism and activation observed following PRT treatment in PAS and low plasma carryover, the results suggest that treatment and storage of platelets in PAS is no more detrimental to platelets than treatment and storage in plasma. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4716049</comments>
            <pubDate>Thu, 14 Apr 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4716049</guid>        </item>
        <item>
            <title>Diary of Events</title>
            <link>http://www.medworm.com/index.php?rid=4710799&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01503.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4710799</comments>
            <pubDate>Thu, 14 Apr 2011 17:51:57 +0100</pubDate>
            <guid isPermaLink="false">4710799</guid>        </item>
        <item>
            <title>Addendum to Vox Sanguinis 2011, 100: 436–437</title>
            <link>http://www.medworm.com/index.php?rid=4710798&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01460.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4710798</comments>
            <pubDate>Thu, 14 Apr 2011 17:51:56 +0100</pubDate>
            <guid isPermaLink="false">4710798</guid>        </item>
        <item>
            <title>Intensive plasmapheresis donations contain less immunoglobulin and albumin: consequences for donor health</title>
            <link>http://www.medworm.com/index.php?rid=4710797&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01449.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4710797</comments>
            <pubDate>Thu, 14 Apr 2011 17:51:55 +0100</pubDate>
            <guid isPermaLink="false">4710797</guid>        </item>
        <item>
            <title>Response to Laub et al., ‘Specific protein content of pools of plasma for fractionation from different sources: impact of frequency of donations’, Vox Sanguinis (2010) 99, 220–231</title>
            <link>http://www.medworm.com/index.php?rid=4710796&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01448.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4710796</comments>
            <pubDate>Thu, 14 Apr 2011 17:51:54 +0100</pubDate>
            <guid isPermaLink="false">4710796</guid>        </item>
        <item>
            <title>Red cells from the original JAL+ proband are also DAK+ and STEM+</title>
            <link>http://www.medworm.com/index.php?rid=4687238&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01465.x</link>
            <description>Conclusion  J.Allen’s RBCs express the low‐prevalence Rh antigens, JAL, V/VS (extremely weakly), STEM, and DAK. The presence of JAL on the variant Rhce, RhceJAL (16Cys, 114Trp, 245Val), STEM on the variant Rhce, RhceBI (16Cys, 238Val, 273Val, 378Val), and DAK on the variant RhD (170Thr, 223Val), encoded by RHD*DOL in trans to RHCE*ceBI is consistent with expression of these antigens. When J. Allen RBCs are used to detect and identify an anti‐JAL, it is important to remember that they also express STEM and DAK. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4687238</comments>
            <pubDate>Thu, 07 Apr 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4687238</guid>        </item>
        <item>
            <title>Mortality after transfusions, relation to donor sex</title>
            <link>http://www.medworm.com/index.php?rid=4687237&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01487.x</link>
            <description>Conclusions  Overall transfusions from female donors were not associated with increased mortality. However, male recipients of blood from female donors did have an increased risk of death. Female recipients of blood from male donors showed a weaker increase in mortality. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4687237</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4687237</guid>        </item>
        <item>
            <title>Detection of granulocyte antibodies using simultaneous analysis of specific granulocyte antibodies assay (SASGA)</title>
            <link>http://www.medworm.com/index.php?rid=4677921&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01470.x</link>
            <description>Conclusion  The SASGA assay permits reliable detection of specific granulocyte antibodies. Six distinct antibodies can be simultaneously determined. This method will potentially open the way to investigations on additional specific antibodies as it facilitates laboratory diagnosis. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4677921</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4677921</guid>        </item>
        <item>
            <title>Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura</title>
            <link>http://www.medworm.com/index.php?rid=4645506&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01476.x</link>
            <description>Conclusions  In clinical studies, IVIG‐L (Nanogam®) demonstrated to be efficacious, well tolerated and safe. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4645506</comments>
            <pubDate>Tue, 29 Mar 2011 16:59:26 +0100</pubDate>
            <guid isPermaLink="false">4645506</guid>        </item>
        <item>
            <title>Methods for testing platelet function for transfusion medicine</title>
            <link>http://www.medworm.com/index.php?rid=4645507&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01467.x</link>
            <description>Conclusion  Specific aspects of platelet function can be assessed by the no/low shear methods, while the high shear methods provide more general analysis of platelet haemostatic competence. Yet, there is no strong evidence that the in vitro data correspond with the clinical outcome. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4645507</comments>
            <pubDate>Mon, 28 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4645507</guid>        </item>
        <item>
            <title>The effect of FFP:RBC ratio on morbidity and mortality in trauma patients based on transfusion prediction score</title>
            <link>http://www.medworm.com/index.php?rid=4632728&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01466.x</link>
            <description>Conclusions  A predictive model of massive transfusion upon admission might be able to rapidly identify which severe trauma patients would benefit or have increased complications from the immediate application of a high ratio of FFP:RBCs. This study helps to identify the appropriate population for a prospective, interventional trial. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4632728</comments>
            <pubDate>Fri, 25 Mar 2011 17:53:16 +0100</pubDate>
            <guid isPermaLink="false">4632728</guid>        </item>
        <item>
            <title>Immunomodulatory effects of therapeutic preparations of human albumin</title>
            <link>http://www.medworm.com/index.php?rid=4617335&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01475.x</link>
            <description>Conclusion  Altogether, these results reveal a possible physiological role of albumin in immunological processes, leading to an increased ability of antigen presenting cells to trigger T cell activation. This immunomodulatory effect needs to be considered, at least in studies in which albumin is used as a presumably inert control protein. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4617335</comments>
            <pubDate>Tue, 22 Mar 2011 17:51:49 +0100</pubDate>
            <guid isPermaLink="false">4617335</guid>        </item>
        <item>
            <title>In vitro storage characteristics of platelet concentrates suspended in 70% SSP+TM additive solution versus plasma over a 14‐day storage period</title>
            <link>http://www.medworm.com/index.php?rid=4607144&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01468.x</link>
            <description>Conclusion  Platelets suspended in a medium of 70:30 SSP+™ to plasma ratio performed at least as well as platelets in 100% autologous plasma for up to 10 days of storage. Further, results are suggestive of an apoptosis‐like process being involved in the platelet storage lesion. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4607144</comments>
            <pubDate>Fri, 18 Mar 2011 17:26:59 +0100</pubDate>
            <guid isPermaLink="false">4607144</guid>        </item>
        <item>
            <title>An association of ABO non‐identical platelet and cryoprecipitate transfusions with altered red cell transfusion needs in surgical patients</title>
            <link>http://www.medworm.com/index.php?rid=4607145&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01464.x</link>
            <description>Conclusions  These results, in the context of previous findings, suggest that providing ABO‐identical platelets and cryoprecipitate might be associated with reduction in transfusion requirements and improve outcomes in surgical patients. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4607145</comments>
            <pubDate>Fri, 18 Mar 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4607145</guid>        </item>
        <item>
            <title>Addendum to the letter by Basavaraju et al, Vox Sanguinis XXX:XXX:XX</title>
            <link>http://www.medworm.com/index.php?rid=4596480&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01460.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4596480</comments>
            <pubDate>Wed, 16 Mar 2011 17:35:27 +0100</pubDate>
            <guid isPermaLink="false">4596480</guid>        </item>
        <item>
            <title>International Society of Blood Transfusion Working Party on red cell immunogenetics and blood group terminology: Berlin report</title>
            <link>http://www.medworm.com/index.php?rid=4581993&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01462.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4581993</comments>
            <pubDate>Mon, 14 Mar 2011 19:09:48 +0100</pubDate>
            <guid isPermaLink="false">4581993</guid>        </item>
        <item>
            <title>Diary of Events</title>
            <link>http://www.medworm.com/index.php?rid=4571856&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2011.01481.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4571856</comments>
            <pubDate>Fri, 11 Mar 2011 17:25:05 +0100</pubDate>
            <guid isPermaLink="false">4571856</guid>        </item>
        <item>
            <title>Preparation of granulocyte concentrates by apheresis: collection modalities in the USA</title>
            <link>http://www.medworm.com/index.php?rid=4478759&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01417.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4478759</comments>
            <pubDate>Tue, 01 Feb 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4478759</guid>        </item>
        <item>
            <title>Diary of Events</title>
            <link>http://www.medworm.com/index.php?rid=4332829&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01463.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4332829</comments>
            <pubDate>Wed, 12 Jan 2011 16:42:52 +0100</pubDate>
            <guid isPermaLink="false">4332829</guid>        </item>
        <item>
            <title>Erratum</title>
            <link>http://www.medworm.com/index.php?rid=4282689&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01451.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4282689</comments>
            <pubDate>Thu, 23 Dec 2010 17:15:40 +0100</pubDate>
            <guid isPermaLink="false">4282689</guid>        </item>
        <item>
            <title>Diary of Events</title>
            <link>http://www.medworm.com/index.php?rid=4282687&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01457.x</link>
            <description>(Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4282687</comments>
            <pubDate>Thu, 23 Dec 2010 17:15:39 +0100</pubDate>
            <guid isPermaLink="false">4282687</guid>        </item>
        <item>
            <title>HLA, immunogenetics, pharmacogenetics and personalized medicine</title>
            <link>http://www.medworm.com/index.php?rid=4282686&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01438.x</link>
            <description>Displaying the highest level of diversity of any functional genetic complex with medical impact, the HLA system represents a landmark and a model for the development of predictive and preventive medicine. The massive amount of data which will soon be obtained through new high through put technologies for individual genomes and transcriptomes challenges the HLA and medicine paradigm. Systems biology approach and integrative methodologies will undoubtedly be needed to unravel the ever growing number of HLA and diseases associations and the role of immunogenetics in transplantation and other allogeneic cell therapies. Also HLA, immunogenetics and pharmacogenetics are merging to bring to the individual patient tailored and personalized treatment. Providing insights into the complexities of pre...</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4282686</comments>
            <pubDate>Thu, 23 Dec 2010 17:15:38 +0100</pubDate>
            <guid isPermaLink="false">4282686</guid>        </item>
        <item>
            <title>Umbilical cord blood: current status and future directions</title>
            <link>http://www.medworm.com/index.php?rid=4282685&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01409.x</link>
            <description>Once considered biological waste, umbilical cord blood (UCB) has become an accepted source of haematopoietic stem cells (HSCs). With initial success in the pediatric setting, UCB transplantation continues to gain favor in the adult patient population. Novel approaches to UCB transplantation include use of two units and a variety of graft manipulations. Additional uses for UCB are currently being explored and include applications in regenerative medicine and immunotherapy. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4282685</comments>
            <pubDate>Thu, 23 Dec 2010 17:15:37 +0100</pubDate>
            <guid isPermaLink="false">4282685</guid>        </item>
        <item>
            <title>The functional importance of blood group‐active molecules in human red blood cells</title>
            <link>http://www.medworm.com/index.php?rid=4282684&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01388.x</link>
            <description>Antigens of 23 of the 30 human blood group systems are defined by the amino acid sequence of red cell membrane proteins. The antigens of DI, RH, RHAG, MNS, GE and CO systems are carried on blood group‐active proteins (Band 3, D and CE polypeptides, RhAG, Glycophorins A and B, Glycophorins C and D and Aquaporin 1, respectively) which are expressed at high levels (&amp;gt; 200 000 copies/red cell). These major proteins contribute to essential red cell functions either directly as membrane transporters and by providing linkage to the underlying red cell skeleton or by facilitating the membrane assembly of the protein complexes involved in these processes. The proteins expressing antigens of the remaining 17 blood group systems are much less abundant (&amp;lt; 20 000 copies/red cell) and the...</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4282684</comments>
            <pubDate>Thu, 23 Dec 2010 17:15:37 +0100</pubDate>
            <guid isPermaLink="false">4282684</guid>        </item>
        <item>
            <title>Structural modelling of red cell surface proteins</title>
            <link>http://www.medworm.com/index.php?rid=4282683&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01424.x</link>
            <description>The red cell surface membranes contain a large variety of proteins, many of which express blood group activity as a result of variation in their oligosaccharide or amino acid sequences. To understand the nature of the blood group epitopes, the functions of the proteins that express them and their relationship to each other, computer modelling has been employed to provide predictions of their structures. Modelling is an excellent method of first resort when experimental structural data for the protein of interest are absent or incomplete. The model can then be used to explain previous experimental data and to direct future experiments. In this review, examples of protein modelling are taken from the Rh, RHAG, Kell, LW, Lutheran, Duffy, Dombrock and RAPH blood group systems. (Source: Vox San...</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4282683</comments>
            <pubDate>Thu, 23 Dec 2010 17:15:36 +0100</pubDate>
            <guid isPermaLink="false">4282683</guid>        </item>
        <item>
            <title>Antibody‐mediated (immune) transfusion‐related acute lung injury</title>
            <link>http://www.medworm.com/index.php?rid=4282682&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01392.x</link>
            <description>Antibody‐mediated transfusion‐related acute lung injury (immune TRALI) is now recognized as the most common cause of transfusion‐associated major morbidity and death in the Western world. Among the implicated leucocyte antibodies, these ones directed against the human leucocyte antigens (HLA) class II, human neutrophil alloantigens (HNA)‐3a and HLA‐A2 antigens are frequently associated with severe (artificial ventilation required) and fatal cases. There is accumulating evidence that preventive measures such as transfusion of plasma‐rich blood components from male donors or from donors tested negative for leucocyte antibodies are effective in the reduction of severe and fatal immune TRALI. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4282682</comments>
            <pubDate>Thu, 23 Dec 2010 17:15:35 +0100</pubDate>
            <guid isPermaLink="false">4282682</guid>        </item>
        <item>
            <title>Developing pathogen reduction technologies for RBC suspensions</title>
            <link>http://www.medworm.com/index.php?rid=4282681&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01386.x</link>
            <description>Numerous studies have evaluated a wide variety of photosensitizers and alkylating agents as candidates for a pathogen reduction process to be used in RBC suspensions. The methodologies that produce robust inactivation of pathogens with maintenance of RBC properties during storage involve those that specifically target nucleic acids. This has been demonstrated through in vitro studies by flexible photosensitizers, which specifically target nucleic acid but do not engage in photochemistry when free in solution and nucleic acid alkylating agents in conjunction with extracellular quencher(s) to protect against RBC membrane alkylation. The flexible photosensitizer method must be scaled up to entire units, and toxicology studies would need to be performed for further development. Clinical trials...</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4282681</comments>
            <pubDate>Thu, 23 Dec 2010 17:15:35 +0100</pubDate>
            <guid isPermaLink="false">4282681</guid>        </item>
        <item>
            <title>Plasmodium falciparum malaria and the immunogenetics of ABO, HLA, and CD36 (platelet glycoprotein IV)</title>
            <link>http://www.medworm.com/index.php?rid=4282680&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01429.x</link>
            <description>Plasmodium falciparum malaria has long been a killer of the young, and has selected for polymorphisms affecting not only erythrocytes, but the immunogenetics of three histocompatibility systems: ABO, human leukocyte antigen (HLA), and CD36. The ABO system is important because the original allele, encoding glycosylation with the A sugar, acts as an adhesion ligand with infected red blood cells (iRBC), thereby promoting vasoocclusion. The prevalence of blood group O, which reduces this cytoadhesion, has increased in endemic areas. Other adaptations which could mitigate A‐mediated rosetting include weaker A expression and increased soluble A secretion. The role of the HLA system in malaria has been harder to verify. Although HLA‐B53 and DRB1*04 may be associated with clinical outcome, HLA...</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4282680</comments>
            <pubDate>Thu, 23 Dec 2010 17:15:34 +0100</pubDate>
            <guid isPermaLink="false">4282680</guid>        </item>
        <item>
            <title>Hepatitis B, hepatitis C and HIV transfusion‐transmitted infections in the 21st century</title>
            <link>http://www.medworm.com/index.php?rid=4282679&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01426.x</link>
            <description>In the past, transfusion‐transmitted virus (TTV) infections were not uncommon. In recent years with advanced technologies and improved donor screening, the risk of viral transfusion transmission has been markedly reduced. Hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) have all shown marked reduction in transmission rates. However, the newer technologies, including nucleic acid technology (NAT) testing, have affected the residual rates differently for these virally transmitted diseases. Zero risk, which has been the goal, has yet to be achieved. False negatives still persist, and transmissions of these viruses still occur, although rarely. It is known that HBV serological testing misses some infected units; likewise, HBV NAT–negative units have a...</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4282679</comments>
            <pubDate>Thu, 23 Dec 2010 17:15:34 +0100</pubDate>
            <guid isPermaLink="false">4282679</guid>        </item>
        <item>
            <title>Proteomic applications in blood transfusion: working the jigsaw puzzle</title>
            <link>http://www.medworm.com/index.php?rid=4282678&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01433.x</link>
            <description>The application of proteomic technologies to transfusion medicine has opened new avenues to our understanding of the products we prepare for patients and the processes that impact the quality of those products. The development of the field of proteomics has paralleled that of transfusion medicine with over a century of key scientific accomplishments required to bring us to our modern systems. We review the technology of proteomics and its application to transfusion medicine with specific reference to the analysis of blood products, both fractionated and fresh. Although the use of proteomic tools to address transfusion medicine questions is really just beginning, it is clear that this method of analysis provides different insights into unaddressed issues in the area of blood product researc...</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4282678</comments>
            <pubDate>Thu, 23 Dec 2010 17:15:33 +0100</pubDate>
            <guid isPermaLink="false">4282678</guid>        </item>
        <item>
            <title>Recombinant plasma proteins</title>
            <link>http://www.medworm.com/index.php?rid=4282677&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01384.x</link>
            <description>For almost 50 years, the fractionation of human plasma has been the sole possible source of a wide range of therapeutic proteins–such as coagulation factors, anticoagulants, immunoglobulins, and albumin – essential to the treatment of serious congenital or acquired bleeding or immunological diseases. In the last 20 years, the application of recombinant technologies to mammalian cell cultures has made possible – although with some limitations in productivity, costs, and immunogenic risks – to produce and commercialize complex plasma glycoproteins for human therapeutic applications and has opened the way to the development of new molecular entities. Today, the advanced exploration of alternative cell lines and enhanced cell culture systems, as well as the development of alternati...</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4282677</comments>
            <pubDate>Thu, 23 Dec 2010 17:15:32 +0100</pubDate>
            <guid isPermaLink="false">4282677</guid>        </item>
        <item>
            <title>Haemovigilance: an effective tool for improving transfusion practice</title>
            <link>http://www.medworm.com/index.php?rid=4282676&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01442.x</link>
            <description>Haemovigilance is a tool to improve the quality of the blood transfusion chain, primarily focusing on safety. In this review we discuss the history and present state of this relatively new branch of transfusion medicine as well as some developments that we foresee in the near future. The top 10 results and conclusions are:1Haemovigilance systems have shown that blood transfusion is relatively safe compared with the use of medicinal drugs and that at least in Europe blood components have reached a high safety standard.2The majority of the serious adverse reactions and events occur in the hospital.3The majority of preventable adverse reactions are due to clerical errors.4Some adverse reactions such as anaphylactic reactions often are not avoidable and therefore have to be considered as an in...</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4282676</comments>
            <pubDate>Thu, 23 Dec 2010 17:15:32 +0100</pubDate>
            <guid isPermaLink="false">4282676</guid>        </item>
        <item>
            <title>Transfusion practice and safety: current status and possibilities for improvement</title>
            <link>http://www.medworm.com/index.php?rid=4282675&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01366.x</link>
            <description>Audits of practice and incident reporting, most notably to national haemovigilance schemes, indicate that poor hospital transfusion practice is frequent and occasionally results in catastrophic consequences for patients. Improvements in practice are needed and depend on a combined approach including a better understanding of the causes of errors; a reduction in the complexity of routine procedures taking advantage of new technology systems, which enforce agreed guidelines and policies; the setting and regular monitoring of performance standards for key aspects of the hospital transfusion process, improved organisation of transfusion in hospitals and staff training; and further research on the safe and effective use of blood and alternatives to donor blood. There needs to be a greater recog...</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4282675</comments>
            <pubDate>Thu, 23 Dec 2010 17:15:31 +0100</pubDate>
            <guid isPermaLink="false">4282675</guid>        </item>
        <item>
            <title>Red cell storage and prognosis</title>
            <link>http://www.medworm.com/index.php?rid=4282674&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01441.x</link>
            <description>During storage of red blood cells (RBC), these cells develop storage lesions. The clinical relevance of these storage lesions is heavily discussed in literature. In this review, different aspects of the storage lesion are shown and how these potentially affect posttransfusion performance of the RBC. An overview of the conflicting literature on the clinical relevance of prolonged storage is given, summarizing the evidence on associations with mortality, length of stay, (postoperative) infections and organ failure. Subsequently, possible explanations are given for the conflicting results in the clinical studies and suggestions on how to proceed. (Source: Vox Sanguinis)</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4282674</comments>
            <pubDate>Thu, 23 Dec 2010 17:15:31 +0100</pubDate>
            <guid isPermaLink="false">4282674</guid>        </item>
        <item>
            <title>A comparison of health care and blood supply system structures</title>
            <link>http://www.medworm.com/index.php?rid=4282673&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01425.x</link>
            <description>There is great diversity in the practice of blood banking and transfusion medicine between countries. We sought to relate this to the variety of health care and blood supply systems in different countries. Questionnaires were completed by respondents from 15 countries selected from among those with higher Human Development Indices. These data were reviewed searching for correlations with blood banking and transfusion medicine practices. Wide varieties of health care and blood supply schemes were documented. There was no apparent relationship between their structure and organization nor their financing arrangements and their proclivity for the implementation of new methods or approaches such as pathogen inactivation and universal leucoreduction. The costs of the operation of the blood suppl...</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4282673</comments>
            <pubDate>Thu, 23 Dec 2010 17:15:30 +0100</pubDate>
            <guid isPermaLink="false">4282673</guid>        </item>
        <item>
            <title>How much blood is needed?</title>
            <link>http://www.medworm.com/index.php?rid=4282672&amp;cid=s_29472_19_f&amp;fid=29472&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1423-0410.2010.01446.x</link>
            <description>Demographic changes in developed countries as their populations age lead to a steady increase in the consumption of standard blood components. Complex therapeutic procedures like haematopoietic stem cell transplantation, cardiovascular surgery and solid organ transplantation are options for an increasing proportion of older patients nowadays. This trend is likely to continue in coming years. On the other hand, novel aspects in transplant regimens, therapies for malignant diseases, surgical procedures and perioperative patient management have led to a moderate decrease in blood product consumption per individual procedure. The ageing of populations in developed countries, intra‐society changes in the attitude towards blood donation as an important altruistic behaviour and the overall alte...</description>
            <author>Vox Sanguinis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4282672</comments>
            <pubDate>Thu, 23 Dec 2010 17:15:30 +0100</pubDate>
            <guid isPermaLink="false">4282672</guid>        </item>
    </channel>
</rss>

